GD2 and GD3 synthase: novel drug targets for cancer therapy

Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against...

Descripción completa

Detalles Bibliográficos
Autores principales: Sphyris, Nathalie, Sarkar, Tapasree Roy, Battula, Venkata L, Andreeff, Michael, Mani, Sendurai A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905286/
https://www.ncbi.nlm.nih.gov/pubmed/27308452
http://dx.doi.org/10.4161/23723556.2014.975068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905286/
https://www.ncbi.nlm.nih.gov/pubmed/27308452
http://dx.doi.org/10.4161/23723556.2014.975068

Ejemplares similares